NIH Creates Controlled IL-12 Platform for Safer, More Effective Cancer Cell Therapy

National Cancer Institute (NCI) investigators developed DRIM-IL-12, a drug-regulatable, membrane-bound IL-12 cytokine platform, to enhance the safety and efficacy of adoptive cell therapy for cancer. This innovation addresses severe toxicity and control issues in prior IL-12 gene therapies, offering a versatile approach for inducible cytokine regulation and improved outcomes in preclinical models.